Therefore, in addition to the positive impact of bevacizumab on the immune microenvironment and its direct antitumor effect (ORR: 13%–14%), bevacizumab may further enhance this therapeutic effect by inhibiting tumor growth, triggering tumor antigen production, promoting dendritic cell maturation, presenting cancer antigens to T cells, and stimulating tumor infiltration by activated CD8-positive cells during the cancer immunity cycle [23]. The gene discussed is CD8A; the disease is neoplasm.